Avastin (bevacizumab) • carboplatin • Imfinzi (durvalumab) • 5-fluorouracil • capecitabine • leucovorin calcium • datopotamab deruxtecan (DS-1062a) • saruparib (AZD5305) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)

20d

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC (clinicaltrials.gov)

P1, N=15, Not yet recruiting, Presage Biosciences

20 days ago

New P1 trial

Keytruda (pembrolizumab) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)

2ms

FTIH: A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=401, Active, not recruiting, MedImmune LLC | Recruiting --> Active, not recruiting

2 months ago

Enrollment closed • Metastases

Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • volrustomig (MEDI5752)

2ms

MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov)

P1, N=175, Active, not recruiting, AstraZeneca | Trial completion date: May 2023 --> Mar 2026

2 months ago

Trial completion date • Metastases

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

EGFR mutation • ALK fusion

cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • danvatirsen (AZD9150)

3ms

MEDI5752 in Japanese Patients With Advanced Solid Tumors. (clinicaltrials.gov)

P1, N=6, Active, not recruiting, AstraZeneca | Trial primary completion date: Mar 2024 --> Aug 2023

3 months ago

Trial primary completion date • Metastases

volrustomig (MEDI5752)

3ms

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (clinicaltrials.gov)

P2, N=357, Recruiting, AstraZeneca | Phase classification: P1b/2 --> P2 | Trial completion date: Sep 2025 --> Jul 2026 | Trial primary completion date: Sep 2025 --> Jul 2026

3 months ago

Phase classification • Trial completion date • Trial primary completion date • Metastases

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive

Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936) • volrustomig (MEDI5752)

3ms

NeoCOAST-2: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)

P2, N=490, Recruiting, AstraZeneca | N=350 --> 490

3 months ago

Enrollment change

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • datopotamab deruxtecan (DS-1062a) • oleclumab (MEDI9447) • volrustomig (MEDI5752) • AZD0171 • monalizumab (IPH2201)

3ms

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov)

P2, N=260, Recruiting, AstraZeneca | N=180 --> 260 | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025

3 months ago

Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Immunomodulating • Metastases

Avastin (bevacizumab) • cisplatin • gemcitabine • Lenvima (lenvatinib) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)

4ms

eVOLVE-HNSCC: A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (clinicaltrials.gov)

P3, N=1145, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

4 months ago

Enrollment open • Metastases

PD-L1 (Programmed death ligand 1)

PD-L1 expression

volrustomig (MEDI5752)

5ms

TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)

P1; Phase classification: P1b --> P1 | N=232 --> 321

5 months ago

Combination therapy • Enrollment change • Phase classification • Metastases

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

PD-L1 expression

PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx

carboplatin • Imfinzi (durvalumab) • datopotamab deruxtecan (DS-1062a) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)

5ms

MEDISARC-SBRT: Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma (clinicaltrials.gov)

P1, N=20, Recruiting, Institut Claudius Regaud

5 months ago

Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • Metastases

volrustomig (MEDI5752)

5ms

eVOLVE-Meso: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (clinicaltrials.gov)

P3, N=600, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

5 months ago

Enrollment open

Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • pemetrexed • volrustomig (MEDI5752)

5ms

Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03). (ASCO-GI 2024)

Previously, confirmed ORRs of 50% and 43% were reported with T-DXd + 5-fluorouracil (5-FU) and T-DXd + capecitabine (Cap), respectively, in the second-line or later setting in part 1 of DG-03. The protocol was amended to add an additional arm in part 2 and a new part 3, which will investigate T-DXd in combination with a fluoropyrimidine and volrustomig (MEDI5752), a PD-1/CTLA-4 bispecific antibody, in pts with HER2+ and HER2-low (IHC 2+/ISH− or IHC 1+) GC...In arm F of part 2, pts with previously untreated HER2+ GC will be treated with T-DXd + investigator’s choice of 5-FU or Cap + pembrolizumab...Secondary endpoints include safety, duration of response, disease control rate, progression-free survival, overall survival, pharmacokinetics, and immunogenicity. Clinical trial information: NCT04379596.

5 months ago

Clinical • P1/2 data

HER-2 (Human epidermal growth factor receptor 2) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)

HER-2 expression

Keytruda (pembrolizumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • volrustomig (MEDI5752)

5ms

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)

P2, N=240, Recruiting, AstraZeneca | N=80 --> 240

5 months ago

Enrollment change • Metastases

CLDN18 (Claudin 18)

5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • AZD0901 • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)

5ms

eVOLVE-Lung02: A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov)

P3, N=900, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

5 months ago

Enrollment open

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ALK rearrangement • PD-L1 negative • ROS1 rearrangement

Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • volrustomig (MEDI5752)

6ms

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov)

P1, N=179, Recruiting, MedImmune LLC | Phase classification: P1b --> P1 | Trial completion date: Dec 2025 --> Aug 2027 | Trial primary completion date: Dec 2025 --> Aug 2027

6 months ago

Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases

Lenvima (lenvatinib) • Inlyta (axitinib) • volrustomig (MEDI5752)

6ms

P3, N=1145, Not yet recruiting, AstraZeneca

6 months ago

New P3 trial • Metastases

PD-L1 (Programmed death ligand 1)

PD-L1 expression

volrustomig (MEDI5752)

6ms

NeoCOAST-2: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)

P2, N=350, Recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Dec 2028 | Trial primary completion date: Mar 2026 --> Dec 2028

6 months ago

Trial completion date • Trial primary completion date • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

PD-L1 expression

7ms

eVOLVE-Meso: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (clinicaltrials.gov)

P3, N=600, Not yet recruiting, AstraZeneca

7 months ago

New P3 trial • Combination therapy

Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • pemetrexed • volrustomig (MEDI5752)

7ms

MEDISARC-SBRT: Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma (clinicaltrials.gov)

P1, N=20, Recruiting, Institut Claudius Regaud | Not yet recruiting --> Recruiting

7 months ago

Enrollment open • Combination therapy • Metastases

volrustomig (MEDI5752)

7ms

eVOLVECervical: Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (clinicaltrials.gov)

P3, N=1000, Recruiting, AstraZeneca

7 months ago

New P3 trial • IO biomarker • Metastases

PD-L1 (Programmed death ligand 1)

PD-L1 expression • PGR expression

volrustomig (MEDI5752)

9ms

TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)

P1b; Trial completion date: Feb 2025 --> Jan 2026 | Trial primary completion date: Feb 2025 --> Jan 2026

9 months ago

Combination therapy • Trial completion date • Trial primary completion date • Metastases

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

PD-L1 expression

PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx

carboplatin • Imfinzi (durvalumab) • datopotamab deruxtecan (DS-1062a) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)

9ms

eVOLVE-Lung02: A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov)

P3, N=900, Not yet recruiting, AstraZeneca

9 months ago

New P3 trial • Metastases

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ALK rearrangement • PD-L1 negative • ROS1 rearrangement

Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • volrustomig (MEDI5752)

9ms

Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03 (ESMO 2023)

This trial is evaluating T-DXd alone or in combination with durvalumab (durva) or MEDI5752 (a PD-1/CTLA-4 bispecific antibody) with or without chemotherapy in pts with unresectable/metastatic, HER2-OE, nonsquamous NSCLC...In part 1 (enrollment completed), pts with disease progression after 1 or 2 lines of systemic therapy in the recurrent/metastatic setting receive T-DXd monotherapy or T-DXd + durva in combination with cisplatin, carboplatin, or pemetrexed...The primary endpoint is the frequency of adverse events (AEs) and serious AEs (SAEs) with T-DXd + durva + chemotherapy (part 1) or T-DXd + MEDI5752 ± chemotherapy (part 3). Secondary endpoints include confirmed objective response rate, duration of response, disease control rate, progression-free and overall survival, pharmacokinetics, and immunogenicity in all arms as well as the frequency of AEs and SAEs with T-DXd monotherapy (part 1).

9 months ago

Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)

EGFR mutation • HER-2 overexpression • EML4-ALK fusion • ALK fusion

cisplatin • carboplatin • Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • volrustomig (MEDI5752)

9ms

MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC) (ESMO 2023)

Volrustomig with lenvatinib is also being evaluated in 1L aRCC (NCT04522323). Table: 1883MO Efficacy DCO 25Jan2023 M750 M500 Total IMDC Total IMDC F I/P F I/P Response-evaluable, N 32 8 24 33 12 21 ORR, n (%) 15 (46.9) 2 (25) 13 (54.2) 15 (45.5) 7 (58.3) 8 (38.1) CR, n (%) 3 (9.4) 1 (12.5) 2 (8.3) 2 (6.1) 2 (16.7) 0 (0) DCR, n (%) 28 (87.5) 6 (75) 22 (91.7) 23 (69.7) 11 (91.7) 12 (57.1) Progressive disease, n (%) 4 (12.5) – – 8 (24.2) – – mPFS (95% CI), months 11.1 (4.5–NE) – – 9.9 (3.9–NE) – – Per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. CI, confidence interval; CR, complete response; DCR, disease control rate; F, favorable; IMDC, International Metastatic RCC Database Consortium; I/P, intermediate/poor; mPFS, median progression free survival; NE, not estimable.

9 months ago

Clinical • Metastases

PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)

Lenvima (lenvatinib) • volrustomig (MEDI5752)

10ms

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov)

P2, N=180, Recruiting, AstraZeneca | N=120 --> 180

10 months ago

Enrollment change • Combination therapy • Immunomodulating • Metastases

Avastin (bevacizumab) • cisplatin • gemcitabine • Lenvima (lenvatinib) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)

10ms

MEDISARC-SBRT: Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma (clinicaltrials.gov)

P1, N=20, Not yet recruiting, Institut Claudius Regaud | Initiation date: May 2023 --> Sep 2023

10 months ago

Trial initiation date • Combination therapy • Metastases

volrustomig (MEDI5752)

11ms

TAYLOR: MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors. (clinicaltrials.gov)

P2, N=102, Not yet recruiting, Institut Bergonié

11 months ago

New P2 trial

volrustomig (MEDI5752)

11ms

MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov)

P1, N=175, Active, not recruiting, AstraZeneca | N=258 --> 175 | Trial completion date: Mar 2026 --> May 2023 | Trial primary completion date: Mar 2026 --> May 2023

11 months ago

Enrollment change • Trial completion date • Trial primary completion date • Metastases

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

EGFR mutation • ALK fusion

12ms

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)

P2, N=80, Recruiting, AstraZeneca | Trial completion date: Mar 2025 --> Feb 2026 | Trial primary completion date: Jun 2024 --> Aug 2025

12 months ago

Trial completion date • Trial primary completion date • Metastases

5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • rilvegostomig (AZD2936) • volrustomig (MEDI5752)

12ms

DESTINY-Lung03: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (clinicaltrials.gov)

P1, N=168, Recruiting, AstraZeneca | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Dec 2025

12 months ago

Trial completion date • Trial primary completion date • Combination therapy • Metastases

HER-2 overexpression

cisplatin • carboplatin • Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • volrustomig (MEDI5752)

12ms

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov)

P2, N=120, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

12 months ago

Enrollment open • Combination therapy • Immunomodulating • Metastases

Avastin (bevacizumab) • cisplatin • gemcitabine • Lenvima (lenvatinib) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)

1year

TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)

P1b; Trial completion date: Mar 2026 --> Feb 2025

1 year ago

Combination therapy • Trial completion date • Metastases

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

PD-L1 expression

PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx

carboplatin • Imfinzi (durvalumab) • datopotamab deruxtecan (DS-1062a) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)

1year

NeoCOAST-2: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)

P2, N=350, Recruiting, AstraZeneca | N=210 --> 350

1 year ago

Enrollment change • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

PD-L1 expression

over1year

TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)

P1b; N=68 --> 232 | Trial completion date: Jun 2024 --> Mar 2026 | Trial primary completion date: Sep 2023 --> Dec 2024

over 1 year ago

Combination therapy • Trial completion date • Trial primary completion date • Enrollment change

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

PD-L1 expression

PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx

carboplatin • Imfinzi (durvalumab) • datopotamab deruxtecan (DS-1062a) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)

over1year

NeoCOAST-2: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)

P2, N=210, Recruiting, AstraZeneca | N=140 --> 210

over 1 year ago

Enrollment change • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

PD-L1 expression

cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • oleclumab (MEDI9447) • volrustomig (MEDI5752) • monalizumab (IPH2201)

2years

MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov)

P1, N=212, Active, not recruiting, AstraZeneca | Trial completion date: Jan 2024 --> Mar 2026 | Trial primary completion date: Jan 2024 --> Mar 2026

2 years ago

Trial completion date • Trial primary completion date

PD-L1 (Programmed death ligand 1)

cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • volrustomig (MEDI5752) • danvatirsen (AZD9150)

2years

Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial. (ASCO 2022)

MEDI5752 monotherapy showed deep and durable antitumor activity in pts with advanced RCC, despite high rates of treatment D/C, particularly in the 1L setting. To better characterize the risk-benefit profile, MEDI5752 is now being explored at doses <1500 mg in 1L ccRCC expansion cohorts.

2 years ago

Clinical • Checkpoint inhibition

CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)

volrustomig (MEDI5752)

2years

MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study (AACR 2022)

Dose-dependent increases in peripheral T cell proliferation (Ki67+) and activation (ICOS+) plateaued at doses ≥500 mg and demonstrated CTLA-4 specific blockade in the range of tremelimumab 6-10 mg/kg. MEDI5752 showed encouraging antitumor activity with durable clinical benefit. Doses <1500 mg were better tolerated than doses ≥1500 mg. Treatment led to robust dual checkpoint blockade, evidence of T-cell activation and expansion of new and existing T-cell clones at pharmacodynamic levels that exceeded what is clinically feasible with dosing of conventional anti-PD-1 plus anti-CTLA-4 antibodies.

2 years ago

P1 data • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker

PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • ICOS (Inducible T Cell Costimulator)

Imjudo (tremelimumab) • volrustomig (MEDI5752)

almost3years

MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov)

P1, N=212, Active, not recruiting, AstraZeneca | Trial completion date: Oct 2023 --> Jan 2024 | Trial primary completion date: Oct 2023 --> Jan 2024

almost 3 years ago

Clinical • Trial completion date • Trial primary completion date

PD-L1 (Programmed death ligand 1)

cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • volrustomig (MEDI5752) • danvatirsen (AZD9150)

3years

MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov)

P1, N=212, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting

3 years ago

Clinical • Enrollment closed

PD-L1 (Programmed death ligand 1)

cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • volrustomig (MEDI5752) • danvatirsen (AZD9150)